Good news | Jilin Qijian Bio-Pharmaceutical Co., Ltd. passed the pharmaceutical GMP compliance inspection
2024-11-27
[Top]
"Human growth hormone (HGH) injection" received the "Clinical Trial Acceptance Notice" from the National Medical Products Administration(NMPA)!
- Categories:Qijian News
- Author:QIjian
- Origin:QIjian
- Time of issue:2024-10-25
- Views:0
(Summary description)On October 10, 2024, the product "Human growth hormone (HGH) injection" developed by Jilin Qijian Bio-pharmaceutical Co., Ltd. received the "Clinical Trial Acceptance Notice" from the National Medical Products Administration(NMPA)
The development of human growth hormone (HGH) injection is the crystallization of the unremitting efforts and innovative spirit of the R&D team, it not only demonstrate the company's profound foundation and forward-looking vision in the field of bio-pharmaceuticals, but also injected a strong impetus to the overall jump in the company's R&D strength.It marks a breakthrough progress in the company’s research and development of new products in the endocrine field, which will help further optimize the company's product structure, enrich it’s product pipeline, enhance the company's overall R&D capabilities, and enhance the company's long-term profitability.
[Top]
"Human growth hormone (HGH) injection" received the "Clinical Trial Acceptance Notice" from the National Medical Products Administration(NMPA)!
(Summary description)On October 10, 2024, the product "Human growth hormone (HGH) injection" developed by Jilin Qijian Bio-pharmaceutical Co., Ltd. received the "Clinical Trial Acceptance Notice" from the National Medical Products Administration(NMPA)
The development of human growth hormone (HGH) injection is the crystallization of the unremitting efforts and innovative spirit of the R&D team, it not only demonstrate the company's profound foundation and forward-looking vision in the field of bio-pharmaceuticals, but also injected a strong impetus to the overall jump in the company's R&D strength.It marks a breakthrough progress in the company’s research and development of new products in the endocrine field, which will help further optimize the company's product structure, enrich it’s product pipeline, enhance the company's overall R&D capabilities, and enhance the company's long-term profitability.
- Categories:Qijian News
- Author:QIjian
- Origin:QIjian
- Time of issue:2024-10-25
- Views:0
Information
On October 10, 2024, the product "Human growth hormone (HGH) injection" developed by Jilin Qijian Bio-pharmaceutical Co., Ltd. received the "Clinical Trial Acceptance Notice" from the National Medical Products Administration(NMPA)
The development of human growth hormone (HGH) injection is the crystallization of the unremitting efforts and innovative spirit of the R&D team, it not only demonstrate the company's profound foundation and forward-looking vision in the field of bio-pharmaceuticals, but also injected a strong impetus to the overall jump in the company's R&D strength.It marks a breakthrough progress in the company’s research and development of new products in the endocrine field, which will help further optimize the company's product structure, enrich it’s product pipeline, enhance the company's overall R&D capabilities, and enhance the company's long-term profitability.
Keyword:
Scan the QR code to read on your phone
Related News
Contact Us
Contact us
客户留言
Description:
Contact Us
ADD： No.707 Chaofan street, High-Tech Industrial Development Zone, Changchun City, Jilin province, China
Service Hotline：0086-431-86561075
Fax：0086-431-88794098
Email：export@qijianbio.com
Copyright：Jilin Qijian Bio-pharmaceutical Co., Ltd. by:300.cn 吉ICP备20003293号 SEO
搜索